Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. The company is headquartered in Commack, New York and currently employs 14 full-time employees. The company went IPO on 2020-02-18. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The firm's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
Follow-Up Questions
Scienture Holdings Inc (SCNX)'in P/E oranı nedir?
Scienture Holdings Inc 'in P/E oranı 2.0214 'dir
Scienture Holdings Inc 'in CEO'su kimdir?
Mr. Surendra Ajjarapu 2014 'den beri şirketle birlikte olan Scienture Holdings Inc 'in Chairman of the Board 'ıdır.
SCNX hissesinin fiyat performansı nasıl?
SCNX 'in mevcut fiyatı $0.889 'dir, son işlem günde 0% decreased etti.
Scienture Holdings Inc için ana iş temaları veya sektörler nelerdir?
Scienture Holdings Inc Health Care endüstrisine ait ve sektör Health Care 'dir
